Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ADAKVEO safely and effectively. See full prescribing information for ADAKVEO. ADAKVEO® (crizanlizumab-tmca) injection, for intravenous use Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
ADAKVEO® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
- generic_name
- crizanlizumab
- product_names
- crizanlizumab
- ndc
- 0078-0883, 0078-0883-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en